WX-0593 is a potent ALK inhibitor against ALK and ROS1 rearrangement and a series of crizotinib (CRZ)-resistant mutants. We explored the safety and efficacy of WX-0593 in patients (pts) diagnosed with ALK+ or ROS-1+ malignancies, including non-small cell lung cancer (NSCLC). READ ARTICLE
Annals of Oncology DOI:https://doi.org/10.1093/annonc/mdz260.007
Authors: Y-K Shi, J. Fang, S. Zhang, Y. Liu, L. Wang, M. Si, M. Ge and H Geng
